Abstract
BackgroundThe addition of nivolumab to trastuzumab and chemotherapy in first-line unresectable or metastatic HER2 positive esophagogastric adenocarcinoma (HER2+ EGA) results in long progression-free and overall survival as shown by the...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have